The Diabetes Branch of NIDDK has a long-standing interest in the etiology of severe insulin resistance. Initially, we have identified mutations in the insulin receptor gene and studied a group of patients with autoantibodies against the insulin receptor. More recently, we have concentrated on lipoatrophy syndromes: a group of heterogeneous syndromes characterized by lack of adipose tissue and severe insulin reisitance. In a collaboration with Dr. Abhimanyhu Garg (University of Texas Southwestern) and Anne Bowcock (University of Washington, St. Lois), we have reported mutations on the Lamin A/C gene in patients with an autosomal dominant form of familial partial lipodystrophy. Last year, we have reported a linkage of congenital generalized lipodystrophy to chromosome 9q34. We are continuing our efforts to recruit new pedigrees in order to narrow the interval for the latter condition. We have completed a clinical study that demonstrated the efficacy of troglitazone in treatment of metabolic abnormalities in patients with various forms of lipodystrophy. This study also demonstrated that troglitazone increased body fat in these patients as well. The follow up of these patients are ongoing on a newer thiazolidinedione in order to determine if the increase in body will be incremental with prolonged exposure to thiazolidinedione compounds in these patients. More recently, we have initiated a novel research study that will test the efficacy of the adipocyte-derived leptin hormone replacement in ameliorating the metabolic abnormalities in lipoatrophy syndromes. This study provides a unique opportunity to study the peripheral effects of leptin on the muscle and liver. While the major focus has been on lipaotrophy syndromes, we are continuing our efforts to understand the natural history of other severe insulin resistant states. We also have collaborative studies to elucidate the genetic etiology of Alstrom's syndrome and multiple familial lipomatosis.
| Javor, Edward D; Moran, Stephanie Ann; Young, Janice Ryan et al. (2004) Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab 89:3199-207 |
| Musso, Carla; Cochran, Elaine; Moran, Stephanie Ann et al. (2004) Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore) 83:209-22 |
| Moran, Stephanie Ann; Patten, Nicole; Young, Janice Ryan et al. (2004) Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism 53:513-9 |
| Cochran, Elaine; Young, Janice Ryan; Sebring, Nancy et al. (2004) Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. J Clin Endocrinol Metab 89:1548-54 |
| Agarwal, Anil K; Simha, Vinaya; Oral, Elif Arioglu et al. (2003) Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab 88:4840-7 |
| Gorden, Phillip; Gavrilova, Oksana (2003) The clinical uses of leptin. Curr Opin Pharmacol 3:655-9 |
| Petersen, Kitt Falk; Oral, Elif Arioglu; Dufour, Sylvie et al. (2002) Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 109:1345-50 |
| Bolan, Charles; Oral, Elif Arioglu; Gorden, Phillip et al. (2002) Intensive, long-term plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy. J Clin Endocrinol Metab 87:380-4 |
| Oral, Elif Arioglu; Simha, Vinaya; Ruiz, Elaine et al. (2002) Leptin-replacement therapy for lipodystrophy. N Engl J Med 346:570-8 |
| Oral, Elif Arioglu; Ruiz, Elaine; Andewelt, Alexa et al. (2002) Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. J Clin Endocrinol Metab 87:3110-7 |
Showing the most recent 10 out of 15 publications
